Arrow-right Camera

The Spokesman-Review Newspaper The Spokesman-Review

Saturday, October 19, 2019  Spokane, Washington  Est. May 19, 1883
Partly Cloudy Night 41° Partly Cloudy

News

More galleries


News >  Idaho

Killing of orphaned Idaho black bear cub raises questions

UPDATED: Sat., Oct. 19, 2019, 2:06 p.m.

State wildlife officials in central Idaho say they killed an orphaned black bear cub rather than send it to a rehabilitation facility because success isn’t guaranteed, and Idaho already has a healthy black bear population.
News >  Idaho

Eye on Boise: Medicaid enrollment beginning Nov. 1

UPDATED: Sat., Oct. 19, 2019, 4:27 p.m.

Idaho will start enrollment in its newly expanded Medicaid program on Nov. 1, with benefits starting Jan. 1, and the state already has identified about 70,000 people it knows are likely to be eligible and sign up.
News >  Business

Motley Fool: Not a bitter pill

Investing in biotech stocks can be quite risky, with the potential for clinical failures, regulatory setbacks and new competitors. But for risk-tolerant long-term investors, Vertex Pharmaceuticals (Nasdaq: VRTX) is worth a look. The company currently dominates the cystic fibrosisk, or CF, market with its three approved drugs – Kalydeco, Orkambi and Symdeko. Those drugs allow Vertex to treat about 39,000 patients.